Maria Berkman
Director @ Broadview Ventures
Boston, United States
Maria Berkman is a Series A investor at Broadview Ventures in Boston focused on Medical Device and Health Care. Maria Berkman is the Partner of Vensana Capital. Maria Berkman attended the UCLA Anderson School of Management.Maria Berkman, MD, MBA, is a Director, and Head of the MedTech practice at Broadview Ventures.Maria shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities,through due diligence, negotiation of deal structure, and portfolio company board involvement.Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group (now Monitor Deloitte), where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercialization strategy and competitive strategic planning for a broad range of BioPharma and MedTech clients. Prior to joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery, and earned an MBA from the Anderson School of Management at UCLA.Maria serves on the boards of 480 Biomedical, Adient, BioKier, Cardialen, FineHeart, Vascular Graft Solutions, Vectorious, and Zumbro Discovery, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR).In addition to her role at Broadview Ventures, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Maria Berkman invests in
Stages Maria Berkman invests in
Countries Maria Berkman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical Device 9 (45%)
- Health Care 7 (35%)
- Biotechnology 6 (30%)
- Medical 3 (15%)
- Wellness 2 (10%)
Stage
- Series A 6 (30%)
- Debt Financing 4 (20%)
- Seed 2 (10%)
- Series B 2 (10%)
- Series C 2 (10%)
Country
- United States 9 (45%)
- Canada 1 (5%)
- France 1 (5%)
- Israel 1 (5%)
- Ireland 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Relief Cardiovascular is an inQB8 medical technologies portfolio company developing a revolutionary smart implant to decongest heart failure patients. | $12M / Series A / Jan 08, 2025 | ||
| AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. | $28M / Series C / Apr 24, 2024 | ||
| Puzzle Medical is developing the ModulHeart, a modular percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure who are not candidates for heart transplant or surgical mechanical circulatory support. The device’s modular design allows for hemodynamic support through multiplepumps anchored in parallel in the descending aorta. The design is expected to increase accessibility by enabling safe percutaneous implantation to support both renal and cardiac function, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of life. To date, Puzzle Medical has successfully:○ completed its first-in-human study with all patients experiencing improvements in cardiac and kidney function (2022); ○ completed a Seed financing round (2021); ○ built a strong Key Opinion Leaders committee (2021); ○ received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation (2021). | $25.3M / Series A / Feb 09, 2023 | ||
| CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation | $9.2M / Series A / Feb 04, 2022 | ||
| The company intends to use the funds to finance the development of its first product.France-based medical device company focused on innovative technologies in the cardiovascular space | $25.7M / Series B / Jun 01, 2021 | ||
| Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart. | $31M / Series B / Feb 25, 2020 | ||
| CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation | $1.6M / Seed / Sep 12, 2019 | ||
| CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation | $1.7M / Seed / Sep 12, 2019 | ||
| The company intends to use the funds to finance the development of its first product.France-based medical device company focused on innovative technologies in the cardiovascular space | $7.2M / Series A / Mar 22, 2016 | ||
| 480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown,Massachusetts. | Jun 18, 2015 | ||
| See all 20 investments → | |||
Co-Investors
About Broadview Ventures
Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Broadview Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Benjamin Kreitman
Principal
|
|||
Christopher de Souza
Director
|
|||
Daniel Gottlieb
Director
|
|||
|
Maria Berkman
Director
|
|||
Nichole Schiffer
Director of Operations
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Maria Berkman invest in?
Maria Berkman invests primarily in Medical Device, Health Care and Biotechnology startups, most often at Series A and Debt Financing stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Maria Berkman?
Public channels for Maria Berkman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Maria Berkman last invest?
The most recent investment recorded for Maria Berkman closed in Jan 2025. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
